Maynard Um
-
-
-
-
-
-
-
RBC Capital Upgrades Telix Pharmaceuticals Ltd (TLX:AU) (TLX) to Outperform
-
-
-
-
-
-
-
Telix Pharmaceuticals posts $247M in Q2 revenue, raises R&D outlook
-
-
-
-
-
-
-
Telix completes enrollment for first-line glioblastoma study
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Telix Pharmaceuticals Ltd (TLX)
-
-
-
-
-
-
-
Telix partners with Varian on cancer imaging and radiation therapy
-
-
-
-
-
-
-
Telix Pharmaceuticals Ltd (TLX) PT Lowered to $20 at H.C. Wainwright
-
-
-
-
-
-
-
Telix (TLX) announces UK approval of Illuccix
-
478,601 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


